Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Approaches to Cancer Diagnostics

This article was originally published in Start Up

Executive Summary

Genetics and other technological advances are changing cancer diagnostics research, much as they have other areas of medicine, but researchers face, among other hurdles, information overload.

You may also be interested in...



Cancer Diagnostics--Moving Forward, Slowly

After years of confusion and stagnation, the field of cancer biomarker diagnostics seems to be progressing, even as huge challenges remain. Investors are alert but cautious. The sheer volume of funding and attention devoted to proteomics and genomics, along with advances in research tools, have led to new approaches to looking for and developing assays. But with exception of Cytyc Corp., not a lot of successful cancer-oriented diagnostic role models exist for start-ups.

Overcoming Skepticism About Cancer Diagnostics

In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.

Overcoming Skepticism About Cancer Diagnostics

In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037033

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel